Researchers identify a means of controlling a parasite that kills and eats human cells

Entamoeba histolytica, which causes inflammation of the colon (colitis), plays dirty. It attacks and kills human immune cells in seconds. Then the parasite hides the evidence by eating the cells’ corpses. While doing so, it kills nearly 100,000 people each year.

The research team, led by Dr. William Petri, hypothesized that identifying molecules involved in the corpse ingestion might provide insight into how the amebae cause colitis in children.

The team identified a particular protein on the surface of the ameba called a kinase, PATMK. Using a special technique called RNA interference to inhibit the actions of this kinase, they prevented the ameba from eating dead cells.

“By blocking this kinase, we have for the first time prevented the ameba from colonizing and invading the gut,” said Dr. Petri. “This means that we are a step closer to preventing this disease, which wreaks havoc among children worldwide.”

“Infection and further invasion into the gut require the clearance of dead cells in order to prevent immune recognition of the damaged tissue,” says fellow researcher Douglas Boettner. “PATMK is the first individual member of a large family of proteins to be assigned a function related to the clearance of dying tissue during pathogenesis.”

This protein may be a pivotal vaccination target because these preliminary studies show that alterations in PATMK function reduces progression of amoebiasis in mice, Boettner added. “A vaccine that ultimately would prevent this amoeba from clearing the damaged host may attract helpful immune cells which may recognize and eliminate this infection.”

On a global basis, amebiasis affects approximately 50 million people each year, causing diarrhea, malnutrition and nearly 100,000 deaths.

This work shows how infection is dependent upon the ameba’s consumption of dead cells. By identifying the molecule that controls eating, scientists are one step closer to the ultimate goal of preventing disease caused by this parasite.

Source: Public Library of Science

Keeping herpes infection in check: researchers describe immune system strategies
Herpes simplex virus type I can cause bouts of cold sores, blindness and potentially lethal encephalitis when it reawakens from a quiescent state in the nerve cells it infects.
Chemical 'orienteering': how accurately can cells follow a chemical trail to find their way around?
(PhysOrg.com) -- Scientists have long known that single-cell organisms find their way around by detecting chemicals in their surroundings. Now new research out this week in the Proceedings of the National Academy of Sciences (PNAS) journal has shown how accurately cells are able to do this.
HIV drug maraviroc effective for drug-resistant patients
As many as one quarter of HIV patients have drug resistance, limiting their treatment options and raising their risk for AIDS and death. Now, maraviroc, the first of a new class of HIV drugs called CCR5 receptor antagonists, has been shown to be effective over 48 weeks for drug-resistant patients with R5 HIV-1, a variation of the virus found in more than half of HIV-infected patients.
MS patients have higher spinal fluid levels of suspicious immune molecule
A protein that helps keep immune cells quiet is more abundant in the spinal fluid of patients with multiple sclerosis (MS), further boosting suspicion that the protein, TREM-2, may be an important contributor to the disease.
A new therapeutic option for human hepatocyte cancer
p53-impaired tumors may be particularly suitable to parvovirus H-1-induced therapy. Although the p53 deficiency in tumors may induce resistance to chemotherapeutic agents, this will not affect the tumor cell susceptibility to H-1 PV-induced oncolytic infections. The parvovirus H-1 may also overcome other tumor resistance mechanisms developed in these tumor entities. So H-1 PV is a suitable agent to circumvent the resistance of p53-negative human hepatocellular carcinoma (HCC) cells to genotoxic agents, and enhances the apoptotic process which is dependent on functional PML. Thus, H-1 PV may be considered as therapeutic options for HCC, especially for p53-negative tumors.
Viral 'magic bullet' targets cancer cells with help of new compound
Researchers at McGill University and the affiliated Lady Davis Research Institute of the Jewish General Hospital – along with colleagues at the University of Ottawa and the Ottawa Health Research Institute (OHRI)–report a significant breakthrough in the use of viruses to target and destroy cancer cells, a field known as oncolytic virotherapy. Their results were published in the September early edition of the Proceedings of the National Academy of Sciences (PNAS).
Pores open the door to death
(PhysOrg.com) -- Our body is almost constantly being threatened by pathogens and cancerous cells that appear out of the blue. But the body puts up a fight: specialized cells in the immune system smuggle small molecules (granzymes) into cancer cells and those body cells that have fallen prey to viruses. The molecules then trigger off the diseased cells' built-in suicide program. There are two possible ways in which the granzymes gain entry into the cells under attack.
Why some primates, but not humans, can live with immunodeficiency viruses and not progress to AIDS
Key differences in immune system signaling and the production of specific immune regulatory molecules may explain why some primates are able to live with an immunodeficiency virus infection without progressing to AIDS-like illness, unlike other primate species, including rhesus macaques and humans, that succumb to disease.

Researchers identify a means of controlling a parasite that kills and eats human cells

Related stories:

News discussion: